Screener / SEC EDGAR /CIK 0001393434 /10-K filed Feb 5, 2026, compared with Mar 3, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Ocular Therapeutix, Inc OCUL

Compare with peers Embed
Earnings releases

Latest results release: Nov 9, 2026

8-K item 2.02, exhibit 99

What OCUL's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Read and search

Every release, in full · linked to sec.gov

Press release Nov 9, 2026 · EX-99.1

Ocular Therapeutix™ Reports Third Quarter 2026 Financial Results and Business

Open on SEC

Exhibit 99.1 Ocular Therapeutix™ Reports Third Quarter 2026 Financial Results and Business Highlights

AXPAXLI™ NDA submission for wet AMD on track for 4Q 2026 following upcoming SOL-R interim Week 52 safety analysis

Several FDA interactions, including most recent September 2026 Pre-NDA Meeting, reaffirm alignment on submission package under 505(b)(2) pathway

SOL-1 post-hoc analyses presented at AAO and Empire Forum show subjects without early persistent retinal fluid and fluid variability had better visual outcomes with fewer rescues

SOL-R prospectively excludes subjects with early persistent retinal fluid and fluid variability, with preliminary analysis indicating ~20% of otherwise eligible subjects excluded from SOL-R randomization for these reasons

SOL-R primary endpoint moved to Week 40 (from Week 56) to ensure all subjects complete primary efficacy visit before the interim safety analysis in accordance with the FDA-aligned masking plan, with key secondary endpoints at Weeks 56 and 96

SOL-X enrollment continues with plans to implement every 48-week dosing in the open-label protocol based on the durability shown in SOL-1

Commercial readiness activities accelerated with investments in commercial infrastructure, market access planning, and launch execution capabilities

Ocular appoints Riad Sherif, MD, to Board of Directors, bringing extensive global commercial experience at Alcon, Novartis, Sanofi, and Oculis

Cash balance of $530.6 million as of September 30, 2026, with expected runway into 2028 BEDFORD, MA, November 9, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today reported financial results for the third quarter ended September 30, 2026, and provided recent business highlights including upcoming NDA submission plans for AXPAXLI™ (also known as OTX-TKI), its investigational product candidate for the treatment of wet age-related macular degeneration (wet AMD) and diabetic retinal diseases.

“2026 has been a transformational year for Ocular Therapeutix and we are in a strong position as we prepare to submit our NDA for AXPAXLI in wet AMD under the 505(b)(2) regulatory pathway,” said Pravin U. Dugel, MD, Executive Chairman, President and CEO of Ocular Therapeutix. “Frequent injections define today’s wet AMD treatment experience, and we believe AXPAXLI has the transformative potential to drastically reduce the burden on patients and caregivers. Following our positive pre-NDA meeting in September, we remain aligned with the FDA on our planned submission in the fourth quarter. Recent clinical results from our peers underscore the critical importance of molecular potency, sustained durability, and thoughtful clinical trial design – principles that have guided our AXPAXLI development strategy from the outset. SOL-1 post-hoc analyses presented at AAO reinforce AXPAXLI's remarkable sustained anatomical control, with approximately 70% of subjects who were quantitatively dry at Week 8 remaining dry through Week 36 following a single injection, using a strict AI-based fluid analysis that detects even trace fluid. At last week’s Empire Forum in New York City, we presented additional post hoc analyses showing that approximately 28% of AXPAXLI-treated subjects in SOL-1 experienced early persistent retinal fluid. These patients had worse visual outcomes, increased variability in total retinal fluid volume, increased need for supplemental injections, and a 32-week earlier time to first supplemental injection compared to subjects without early persistent fluid in the same period. These findings are particularly encouraging for SOL-R, which was deliberately designed with the goal of randomizing patients with minimal early retinal fluid and fluid variability. Preliminary analyses of SOL-R screening indicate that approximately 20% of otherwise eligible subjects were excluded from randomization due to early persistent retinal fluid or fluid variability. By contrast, this volatile group of patients were not excluded from SOL-1. The combination of axitinib’s differentiated potency, AXPAXLI’s disease control and durability shown in SOL-1, and our disciplined patient selection strategy further strengthens our confidence in the likelihood of SOL-R’s success.”

Dr. Dugelconcluded, “With the competitive landscape evolving, AXPAXLI is now the only intravitreal sustained release maintenance agent with positive Phase 3 data in wet AMD. We believe our opportunity to fundamentally transform the treatment paradigm has never been greater. As such, we are rapidly advancing our commercial readiness, including the addition of Dr. Riad Sherif to our Board of Directors, who brings extensive global commercial experience in ophthalmology at Alcon, Novartis, Sanofi, and Oculis. We continue to progress our diabetic retinopathy program in parallel, as we work expeditiously toward bringing AXPAXLI to patients who urgently need more durable treatment options as quickly as possible.”

Peter K. Kaiser, MD, Chief Development Officer of Ocular Therapeutixadded, “Building on AXPAXLI’s demonstrated durability in SOL-1, we have modified SOL-X to evaluate retreatment every 48 weeks. This change reflects our confidence in AXPAXLI’s sustained disease control with up to 12-month dosing. We expect SOL-X will provide valuable evidence supporting AXPAXLI’s potential role as a long- term maintenance therapy following a brief course of bolus anti-VEGF injections to achieve initial retinal dryness. SOL-R further supports dosing flexibility by evaluating AXPAXLI retreatment every six months. While SOL-R efficacy data are not required for our planned NDA submission, the trial remains important to our U.S. commercial and ex-U.S. regulatory objectives. Following our May Type C meeting we moved the SOL-R primary endpoint to Week 40 to ensure all subjects complete their primary efficacy assessments beforethe planned Week 52 interim safety analysis to preserve the primary endpoint’s statistical integrity and limit operational bias. As we continue to learn more about AXPAXLI, and the population randomized to SOL-R, our confidence in the trial’s success and AXPAXLI’s potential to dramatically reduce treatment burden has never been greater.”

Following completion of positive Pre-NDA Meeting in September 2026, AXPAXLI New Drug Application (NDA) submission on track for 4Q 2026. Consistent with prior communications, the planned AXPAXLI NDA for wet AMD will be supported by SOL-1 Week 52 efficacy data, SOL-1 and interim SOL-R Week 52 safety data, and confirmatory evidence. In connection with the NDA review process, Ocular plans to submit data from subjects who have received multiple AXPAXLI injections in · both Phase 3 trials to support the inclusion of repeat dosing on AXPAXLI’s label, if approved. Ocular believes its extensive regulatory engagement, including the Special Protocol Assessment (SPA) agreement for SOL-1 and positive Type C and Pre-NDA meetings, provide a strong foundation for its planned NDA submission. In alignment with the FDA, Ocular intends to submit the AXPAXLI NDA under the 505(b)(2) regulatory pathway, which has the potential to shorten the FDA review timeline by up to 60 days as compared to the traditional 505(b)(1) pathway for a new molecular entity.

Interim SOL-R Week 52 safety analysis to be conducted in 4Q 2026, with interim safety data to be included in the planned AXPAXLI NDA submission to FDA. Together with the existing SOL-1 safety database, the interim safety analysis of SOL-R subjects who have reached Week 52 will bring the aggregate safety dataset to more than 300 patients with at · least one year of follow-up after AXPAXLI treatment, in line with FDA requirements. The interim SOL-R Week 52 safety results will be included in the NDA submission to the FDA. SOL-R will remain masked through the end of Year 2 (Week 96) as part of the masking plan aligned to with the FDA. This approach is intended to support the Company's regulatory strategy in the United States and internationally.

SOL-R primary endpoint timing updated to Week 40 with topline results on track for 1Q 2028 after key secondary endpoints are evaluated. Ocular has updated the timing of the SOL-R primary efficacy endpoint from Week 56 to Week 40, while maintaining key secondary endpoints at Weeks 56 and 96. The modification was necessary to preserve the integrity of the ongoing masked trial by ensuring all subjects have passed the new primary endpoint visit before the planned · interim Week 52 safety analysis takes place. SOL-R will remain masked through Week 96 to evaluate key secondary and other secondary endpoints of superiority to aflibercept (8 mg), along with prevention of fibrosis and atrophy relative to aflibercept (2 mg). The process to modify the timing of the primary endpoint was initiated in May 2026 after the Company’s Type C Meeting, with subsequent FDA engagement, protocol integration, IRB approval, and FDA alignment completed ahead of the upcoming planned interim safety analysis.

Recent · SOL-1 post hoc analyses further illustrate AXPAXLI’s potential for sustained anatomical control and reinforce SOL-R patient selection strategy.

A post hoc analysis presented at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting reported that at Week 8 in SOL-1, 71% of AXPAXLI-treated subjects were quantitatively dry (≤10nL total retinal fluid volume in 6x6 OCT scan) using an AI-based analysis that detects even trace fluid. Of these subjects, approximately 70% remained quantitatively dry using this very strict criteria through Week 36, highlighting durability of anatomical control in patients who achieved early disease stability in SOL-1.

A subsequent SOL-1 post-hoc analysis presented at the 2026 Empire Forum reported that 28% of the AXPAXLI-treated subjects in SOL-1 had early persistent fluid, defined as change in central subfield thickness (CSFT) of >30µm from baseline at Week 8. It is unlikely that these subjects would have qualified for randomization in SOL-R, based on the non-inferiority trial’s exclusion criteria during the screening period. Subjects with early persistent fluid in SOL-1 had worse visual outcomes, a 32-week earlier time to supplemental injection, and an increased frequency of needing supplemental injections, compared to subjects without early persistent fluid in the same period.

These post hoc analyses reinforce the Company's confidence in AXPAXLI's potential to deliver predictable, sustained disease control with significantly fewer injections than currently available therapies.

Preliminary analysis of screen failures in SOL-R indicates that approximately 20% of otherwise eligible subjects were excluded due to early persistent fluid or fluid fluctuations. These findings provide additional support for the SOL-R study’s differentiated design, which incorporates a six-month pre-randomization period to screen-out patients with high fluid fluctuations · and select patients without early persistent fluid for randomization. The approximate 20% of otherwise eligible subjects that were excluded due to early persistent fluid or fluid fluctuations aligns with Ocular’s expectations prior to SOL-R, based on historical literature, and is validated by similar findings in SOL-1. Together, these findings provide confidence that SOL-R is randomizing the intended patient population and increases the Company’s conviction in SOL-R’s potential success.

Commercial readiness advancing rapidly as AXPAXLI is well positioned to potentially be the first intravitreal sustained release maintenance agent approved for wet AMD. Ocular continues to advance commercial readiness activities in anticipation of a potential U.S. launch of AXPAXLI, if · approved, with ongoing investments in commercial infrastructure, market access planning, and launch execution capabilities. Ocular’s market research indicates strong physician interest in AXPAXLI’s profile based on SOL-1 data alone and launch planning activities are designed to support rapid physician adoption and broad patient access following a potential regulatory approval.

Ocular Therapeutix appoints Riad Sherif, MD, to Board of Directors, who joins Ocular with extensive global commercial leadership experience spanning Alcon, Novartis, Sanofi, and Oculis. Dr. Sherif will overlap with Seung Suh Hong, PhD, until the end of this year, at which point · Dr. Hong will step down from the Board. Dr. Sherif is an accomplished ophthalmology executive with decades of commercial strategy, organizational leadership and global market development experience. As Ocular advances AXPAXLI toward potential regulatory approval, the Company believes Dr. Sherif’s strategic insights and commercial perspective will be tremendous assets to our Board.

Dr. Sherif currently serves as Chief Executive Officer and Director of Oculis Holding AG. Prior to joining Oculis, Dr. Sherif served as Entrepreneur in Residence at the Novartis Venture Fund from 2016 to 2017. Previously, he served as President of Europe, Middle East and Africa at Alcon from 2014 to 2016, where he held senior leadership responsibility across a broad international ophthalmology business. In addition to his leadership role at Oculis, Dr. Sherif currently serves as a member of the Board of Directors of Revenio Group corporation.

SOL-X (wet AMD) enrollment momentum continues as Ocular plans to modify the dosing cadence to every 48 weeks. To date, the vast majority of trial investigators and eligible patients have chosen to participate in SOL-X. Subjects who have successfully completed two-year follow-up in either SOL-1 or SOL-R are eligible to enroll in the three-year · open-label extension study evaluating the long-term safety and outcomes of AXPAXLI treatment. Based on AXPAXLI’s demonstrated durability of up to 48 weeks in SOL-1, Ocular plans to modify the SOL-X dosing interval to reflect potential durability of real-world dosing of AXPAXLI. Ocular believes sustained VEGF suppression with AXPAXLI may reduce the incidence of fibrosis and atrophy in wet AMD, thereby improving long-term outcomes.

Together, the Company’s three wet AMD trials serve distinct and complementary objectives. SOL-1 demonstrated AXPAXLI’s superiority to a single aflibercept (2 mg) injection, with durability extending beyond 48 weeks in many subjects. SOL-R is designed to demonstrate non-inferiority to Q8W aflibercept (2 mg) and that AXPAXLI can be safely dosed every six months in all subjects, while also evaluating AXPAXLI’s potential superiority to aflibercept (8 mg). SOL-X will evaluate durable 48-week dosing intervals and the potential long-term visual and anatomical benefits of initiating AXPAXLI treatment earlier in the disease course. Collectively, these studies are designed to support a comprehensive clinical profile that reinforces AXPAXLI’s potential efficacy, durability, and flexibility in clinical practice.

HELIOS-3 (Phase 3, non-proliferative diabetic retinopathy, NPDR) enrollment progressing as Ocular’s potential single registrational trial in diabetic retinopathy. HELIOS-3 · evaluates AXPAXLI dosed every 12 months (Q48W) versus sham in approximately 620 patients and is designed to support a potential broad label in diabetic retinal disease, including patients with non-center-involved diabetic macular edema (DME).

Total cash and cash equivalentswere $530.6 million as of September 30, 2026. Based on current plans and related estimates of anticipated cash inflows from DEXTENZA ®, the Company believes that its current cash balance is sufficient to support its planned operating expenses, debt service obligations and capital expenditure requirements into 2028. This cash projection factors in the completion of the SOL-1 trial and the continued execution of the SOL-R, the SOL-X and the HELIOS-3 trials. The cash projection includes investment in pre- commercial activities and preparations for the potential FDA approval and initial launch of AXPAXLI. It does not include the full expenses the Company anticipates it needs to scale its manufacturing capacity and commercial team, if approved.

Total net revenuewas $12.9 million for the third quarter of 2026, compared with $14.5 million for the comparable quarter of 2025.

Research and development expensesfor the third quarter of 2026 were $74.8 million versus $52.4 million for the comparable quarter in 2025. The year over year increase in R&D expenses resulted from an acceleration in enrollment in the Company’s HELIOS-3 diabetic retinopathy study and SOL-X long-term extension study, as well as increased headcount and infrastructure to support expanded clinical trial activity.

Selling and marketing expenseswere $15.7 million for the third quarter of 2026, compared with $13.1 million for the comparable quarter of 2025, reflecting an increase in personnel and pre-commercial investments to prepare for a potential AXPAXLI wet AMD launch.

General and administrative expenseswere $18.8 million for the third quarter of 2026, compared with $16.0 million for the comparable quarter of 2025 reflecting increased personnel costs and additional infrastructure to support an increased scope of clinical trials and manufacturing expansion.

Net loss for the third quarter of 2026was $(94.8) million, or a net loss of $(0.42) per share on both a basic and diluted basis, compared with a net loss of $(69.4) million, or a net loss of $(0.38) per share on a basic and diluted basis, for the comparable quarter of 2025.

Ocular Therapeutix will host a conference call and webcast on Monday, November 9, 2026, at 8:00 AM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2026. To access the call, please dial: 1-833-419-0865 (U.S.) or 1-785-838-9333 (International). The live webcast can be accessed HERE (Conference ID: OCULAR) and the live and archived webcast can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcast will be archived for at least 30 days.

AXPAXLI™ (also known as OTX-TKI) is an investigational, bioresorbable, intravitreal hydrogel incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor with anti-angiogenic properties, being evaluated for the treatment of wet AMD and diabetic retinal disease.

The safety and efficacy profile of AXPAXLI has not been established by the FDA or any other regulatory authority, and AXPAXLI has not been approved for marketing.

The registrational Phase 3 SOL-1 trial (NCT06223958) is designed to evaluate the safety and efficacy of AXPAXLI in a multi-center, double-masked, randomized (1:1), parallel group trial that involves more than 100 clinical trial sites located in the U.S. and Argentina. In December 2024, the trial completed randomization of 344 treatment-naïve subjects with a diagnosis of wet AMD in the study eye. Two randomized subjects withdrew from the trial prior to receiving Day 1 treatment.

The superiority trial has an eight-week loading segment prior to randomization. During the loading segment, subjects who have 20/80 vision or better and a central subfield thickness (CSFT) of ≤500 μm receive two doses of aflibercept (2 mg) at Week -8 and Week -4. Subjects who achieve best corrected visual acuity (BCVA) of 20/20 at Day 1 (baseline) or gain at least 10 Early Treatment Diabetic Retinopathy Study (ETDRS) letters at Day 1 along with a CSFT of ≤350 μm were then randomized to receive a single dose of AXPAXLI (0.45 mg) or a single dose of aflibercept (2 mg). At Week 52 and at Week 76, all subjects are re-dosed with their respective initial treatment of AXPAXLI (0.45 mg) or aflibercept (2 mg). Subjects will be followed for safety until the end of Week 104.

Throughout the trial, subjects are assessed monthly. Trial subjects and designated trial personnel will remain masked through the end of Week 104. The clinical trial protocol requires that, during the trial, subjects in either arm meeting the pre-specified rescue criteria, which include a BCVA loss of ≥15 ETDRS letters from baseline or new vision-threatening macular hemorrhage, will receive a supplemental dose of aflibercept (2 mg). The protocol provides that after the first rescue injection, rescue therapy may be provided at investigator discretion per their clinical judgement.

The primary endpoint of SOL-1 is the proportion of subjects who maintain visual acuity, defined as a loss of <15 ETDRS letters of BCVA from baseline, at Week 36. Predefined statistical rules were applied to adjust for treatment discontinuation or deviation as per the pre-specified statistical analysis plan. The trial remained masked following Week 36 and subjects were evaluated for treatment durability at Week 52. The trial is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA.

In February 2026, Ocular reported positive SOL-1 Week 52 topline data. The superiority primary endpoint was met with 74.1% of subjects in the AXPAXLI (0.45 mg) arm maintaining vision at Week 36, a 17.5% risk difference (p=0.0006), compared to the aflibercept (2 mg) arm. A key secondary endpoint was met with 65.9% of subjects treated with AXPAXLI (0.45 mg) maintaining vision at Week 52, a 21.1% risk difference (p<0.0001), compared to the aflibercept (2 mg) arm.

The registrational Phase 3 SOL-R trial (NCT06495918) is designed to evaluate the safety and efficacy of AXPAXLI in a multi-center, double-masked, randomized (2:2:1), three-arm trial that includes sites located in the U.S., Argentina, India, and Australia in subjects who are treatment-naïve or were diagnosed with wet AMD in the study eye within about four months prior to enrollment. Further, to qualify for screening, a subject’s study eye must have had a BCVA ETDRS letter score of ≥34 (~20/200). In December 2025, the trial completed the randomization of 640 subjects.

This non-inferiority trial includes a patient enrichment strategy over the six months prior to randomization that includes three screening doses of any anti- VEGF therapy, excluding brolucizumab-dbll, and monitoring to exclude those subjects with early persistent fluid or significant retinal fluid fluctuations. Subjects who continue to meet eligibility, defined as a CSFT of ≤350 μm at Week -12 and Week –8, with ≤35 μm CSFT increase at Week -8 from the lowest CSFT at any prior visit, entered a run-in period and received two loading doses of aflibercept (2 mg) prior to Day 1. Subjects in the first arm receive a single dose of AXPAXLI (0.45 mg) at Day 1 and are re-dosed at Weeks 24, 48, and 72. Subjects in the second arm receive aflibercept (2 mg) on Day 1 and per label every eight weeks thereafter. Subjects in the third arm receive a single dose of aflibercept (8 mg) at Day 1 and are re-dosed at Weeks 24, 48, and 72, aligned with the AXPAXLI treatment arm for adequate masking. Subjects will be followed for safety until the end of Week 96. Throughout the trial, subjects are assessed monthly. Trial subjects and designated trial personnel will remain masked through the end of Week 96. Subjects in any arm that meet pre-specified rescue criteria will receive a supplemental dose of aflibercept (2 mg). The pre- specified rescue criteria include a >5-letter loss in visual acuity plus a ≥75 μm increase in CSFT.

The primary endpoint of SOL-R is to demonstrate non-inferiority in mean BCVA change from baseline between the AXPAXLI and on-label aflibercept (2 mg) arms at Week 40. The non-inferiority margin for the lower bound of the 95% confidence interval is -4.5 letters of mean BCVA when compared to aflibercept (2 mg) dosed every eight weeks.

The SOL-X trial (NCT07516132) is a multi-center, 36-month open-label extension trial designed to evaluate the long-term safety, efficacy, and disease modifying potential of AXPAXLI in wet AMD for subjects who have successfully completed their two-year safety follow-up visits in either the SOL-1 or SOL-R trials. The first subject enrolled in the study in April 2026.

According to the trial design, all subjects will be given AXPAXLI every 48 weeks, starting at Day 1 (after completion of the Week 104 visit in SOL-1, or Week 96 visit in SOL-R), and again at Weeks 48, and 96. Subjects are assessed at Week 4, Week 12, and then every 12 weeks thereafter. Additional visits can be conducted with supplemental anti-VEGF injection administered based on investigator discretion.

The primary objectives of SOL-X are to evaluate the long-term safety of AXPAXLI; to explore long-term visual outcomes, including visual acuity and the incidence and/or progression of fibrosis and macular atrophy; and to evaluate the impact of delayed initiation of AXPAXLI in patients who initially were randomized to receive aflibercept in either SOL-1 or SOL-R.

The registrational Phase 3 HELIOS-3 trial (NCT07235085) is designed to evaluate the safety and efficacy of AXPAXLI in a multi-center, double-masked, randomized (1:1) two-arm superiority trial. The trial is designed to enroll approximately 620 subjects with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) without center-involved diabetic macular edema (CI-DME). The first patient was randomized in the HELIOS-3 trial in November 2025.

Subjects in the first arm receive a single dose of AXPAXLI at Day 1 and are re- dosed at Week 48. Subjects in the second arm receive a sham injection at Day 1 and Week 48 aligned with the AXPAXLI treatment arm for adequate masking. Throughout the trial, subjects are assessed every 4 weeks from Day 1 through Week 56 and every other month thereafter through Week 96.

The primary endpoint of HELIOS-3 is the ordinal diabetic retinopathy severity score (DRSS) 2-step change status at Week 56 from baseline (≥2-step improvement, ≥2-step worsening, less than 2-step change in either direction).

Wet age-related macular degeneration (wet AMD) is a leading cause of severe, irreversible vision loss affecting approximately 14.8 million individuals globally and 1.8 million in the United States alone. Wet AMD causes vision loss due to abnormal new blood vessel growth and hyperpermeability and associated retinal vascularity in the macula, which is primarily stimulated by local upregulation of vascular endothelial growth factor (VEGF). Without prompt and continuous treatment to control this exudative activity, patients develop irreversible vision loss. With proper treatment, patients may maintain visual function for a period of time and may temporarily regain lost vision. Challenges with current therapies include pulsatile, repeated intraocular injections, treatment-related adverse events and up to 40% patient discontinuation within one year of initiating treatment with continued disease progression. Taken together, these factors lead to undertreatment and a lack of long-term vision improvement for patients.

Diabetic retinal disease is an increasingly prevalent global health concern, driven by the rapidly rising number of individuals diagnosed with diabetes each year.

Diabetic retinopathy (DR) is the most common category of retinal diseases, affecting over an estimated 103 million people worldwide. DR is a progressive condition in which retinal blood vessels are damaged following a cascade of events triggered by chronically elevated levels of blood glucose. As many as half of all diabetic patients are expected to develop some form of DR in their lifetime. DR can progress from the non-proliferative (NPDR) stages to the proliferative (PDR) stage characterized by the growth of abnormal new blood vessels. Fewer than 1% of the 6.4 million NPDR patients in the U.S. receive treatment today, despite the availability of anti-VEGF therapies approved for the indication, largely due to the burden of frequent injections.

Diabetic macular edema (DME) is also a leading cause of vision loss in the working-age population. DME, the result of an accumulation of fluid in the macula that can afflict patients with diabetes, can occur at any stage of DR. In patients with DME, blood vessels in the eyes leak and start to swell, which can cause vision loss or blindness. Anti-VEGF drugs are approved to treat DME, but these treatments typically require frequent intravitreal injections, placing a significant burden on patients and physicians alike.

Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel- based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD) and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).

Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA ®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.

DEXTENZA ®is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

This press release contains forward-looking statements of the Company regarding its future expectations, plans, and prospects; statements regarding the development and regulatory status of the Company’s product candidate AXPAXLI (also known as OTX-TKI), including the Company’s intention to submit and timing of a new drug application for AXPAXLI for the treatment of wet AMD based on Week 52 efficacy and safety data from the Company’s SOL-1 Phase 3 clinical trial, Week 52 data from an interim safety analysis to be conducted in the Company’s SOL-R clinical trial, and confirmatory evidence, and planned amendments to the clinical trial protocol of the Company’s SOL-X clinical trial; statements regarding the timing, design, enrollment, randomization, conduct and retention of subjects in the Company’s ongoing and planned clinical trials for AXPAXLI, including the SOL-1, SOL-R and SOL-X clinical trials for the treatment of wet AMD and the HELIOS-3 trial for non-proliferative diabetic retinopathy; statements regarding the commercial potential of AXPAXLI, including market research findings; statements regarding the timing of the availability of data from the SOL-R trial; statements regarding the potential commercialization of AXPAXLI, including statements regarding the potential pricing and label of AXPAXLI and the timing of a potential commercial launch of AXPAXLI, if approved; statements regarding the Company’s plans to leverage the Section 505(b)(2) pathway and its potential to accelerate the review timeline of the Company’s planned NDA submission; statements regarding the Company’s cash runway and the sufficiency of the Company’s cash resources; statements regarding the potential utility or adoption, if approved, of any of the Company’s product candidates, including AXPAXLI; and other statements containing the words “anticipate”, “believe”, “estimate”, “expect”, “intend”, “designed”, “goal”, “may”, “might”, “plan”, “position”, “predict”, “project”, “target”, “potential”, “will”, “would”, “could”, “should”, “continue”, and similar expressions, all of which constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company’s development programs, future results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, uncertainties regarding the initiation, design, timing, conduct and outcomes of the Company’s ongoing clinical trials, including the Company’s SOL-1 trial, SOL-R trial, HELIOS-3 trial, and SOL-X trial; the timing and costs involved in commercializing any product or product candidate that receives regulatory approval; the risk that the U.S. Food and Drug Administration, or FDA, will not agree with the Company’s interpretation of the written agreements under the Special Protocol Assessments for AXPAXLI, including for the SOL-1 trial, or of the minutes of the Company’s Type C and Pre-NDA meetings with the FDA; uncertainty as to whether the FDA will accept a new drug application for AXPAXLI on the basis of a single pivotal clinical trial, notwithstanding discussions the Company has had with the FDA regarding its planned NDA submission; uncertainty as to the minimum clinical data required to demonstrate the safety of a proposed product candidate such as AXPAXLI, even if the FDA recognizes that only one pivotal clinical trial may be required to demonstrate efficacy and accepts the Company’s NDA submission; the risk that even though the FDA has agreed with the overall design of the SOL-1 trial, the FDA may not find that the data generated by the trial and submitted by the Company are sufficient to demonstrate the safety and efficacy of AXPAXLI to the degree necessary to support marketing approval for wet AMD; the risk that the FDA might not agree to the Company’s design, protocol, and statistical analysis plan of any of its clinical trials for which the Company has not obtained a Special Protocol Assessment, including the SOL-R trial; the risk that the Company and the FDA may not agree on, or maintain agreement with respect to, the registrational pathway for any of its product candidates, including AXPAXLI; uncertainty as to whether the Company will be able to timely satisfy the FDA’s other requirements for regulatory approval of AXPAXLI, including the FDA’s Chemistry, Manufacturing and Control’s requirements, even if the Company can satisfy the FDA’s clinical requirements to demonstrate safety and efficacy; uncertainty as to whether the Company’s NDA will qualify for, or whether the FDA will agree to review the NDA, if accepted for filing, under the 505(b)(2) pathway, notwithstanding discussions the Company has had with the FDA regarding its planned regulatory pathway, and whether the 505(b)(2) pathway will provide any time-savings as compared to the traditional 505(b)(1) pathway; uncertainty as to what restrictions, if any, may be imposed on the label for AXPAXLI, if approved, pending the receipt of additional clinical data or otherwise; uncertainty as to whether the data from earlier clinical trials will be predictive of the data of later clinical trials, particularly later clinical trials that have a different design or utilize a different formulation than the earlier trials, whether preliminary or interim data from a clinical trial or post-hoc analyses of clinical data will be predictive of final data from such trial, or whether data from a clinical trial assessing a product candidate for one indication will be predictive of results in other indications; uncertainty as to the Company’s ability to retain regulatory approval of any product or product candidate that receives regulatory approval; uncertainty as to whether data from the Company’s SOL-X trial will demonstrate additional clinically meaningful, long-term benefits; uncertainties regarding the potential commercial advantages and/or position of the Company’s product candidates; uncertainty regarding the implementation and impact of most-favored-nation and other reference pricing regimes on the commercial potential of AXPAXLI, especially in markets outside the United States; availability of data from clinical trials and expectations for regulatory submissions and approvals; the Company’s scientific approach and general development progress; uncertainties inherent in estimating the Company’s cash runway, future expenses and other financial results, including its ability to fund future operations, including clinical trials; the Company’s existing indebtedness and the ability of the Company’s creditors to accelerate the maturity of such indebtedness upon the occurrence of certain events of default; and other factors discussed in the “Risk Factors” section contained in the Company’s quarterly and annual reports on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date of this press release. The Company anticipates that subsequent events and developments may cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.

Investors & Media Ocular Therapeutix, Inc. Bill Slattery Vice President, Investor Relations [email protected] Ocular Therapeutix, Inc.

Assets Current September 30, December 31, assets: 2026 2025 ────────────────────────────────────────────────────────────────────────────── Cash and cash $ 530,612 $ 737,060 equivalents Accounts receivable, 31,388 30,650 net Inventory 4,260 3,564 Prepaid expenses and other 8,340 10,855 current assets Total current 574,600 782,129 assets Property and equipment, 20,281 19,676 net Restricted 1,614 1,614 cash Operating 5,926 4,638 lease assets Other non-current 3,226 — assets Total assets $ 605,647 $ 808,057 Liabilities and Stockholders’ Equity Current liabilities: Accounts $ 5,745 $ 4,154 payable Accrued expenses and 54,440 43,835 other current liabilities Operating lease 2,832 2,817 liabilities Total current 63,017 50,806 liabilities Other liabilities: Operating lease liabilities, 3,646 2,815 net of current portion Derivative 9,547 13,903 liability Deferred 14,000 14,000 revenue Notes 73,535 71,336 payable, net Other non-current 953 887 liabilities Total 164,698 153,747 liabilities Commitments and contingencies Stockholders’ equity: Preferred stock, $0.0001 par value; 5,000,000 shares authorized and no shares — — issued or outstanding at September 30, 2026 and December 31, 2025, respectively Common stock, $0.0001 par value; 400,000,000 and 400,000,000 shares authorized and 219,884,956 22 22 and 215,927,600 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively Additional paid-in 1,860,107 1,811,311 capital Accumulated (1,419,180 ) (1,157,023 ) deficit Total stockholders’ 440,949 654,310 equity Total liabilities and $ 605,647 $ 808,057 stockholders’ equity

Full text with the tables
                                                                    Exhibit 99.1
 Ocular Therapeutix™ Reports Third Quarter 2026 Financial Results and Business  
                                   Highlights                                   
                                                                                
  AXPAXLI™ NDA submission for wet AMD on track for 4Q 2026 following upcoming   
                     SOL-R interim Week 52 safety analysis                      
                                                                                
Several FDA interactions, including most recent September 2026 Pre-NDA Meeting, 
        reaffirm alignment on submission package under 505(b)(2) pathway        
                                                                                
SOL-1 post-hoc analyses presented at AAO and Empire Forum show subjects without 
early persistent retinal fluid and fluid variability had better visual outcomes 
                               with fewer rescues                               
                                                                                
 SOL-R prospectively excludes subjects with early persistent retinal fluid and  
   fluid variability, with preliminary analysis indicating ~20% of otherwise    
     eligible subjects excluded from SOL-R randomization for these reasons      
                                                                                
 SOL-R primary endpoint moved to Week 40 (from Week 56) to ensure all subjects  
complete primary efficacy visit before the interim safety analysis in accordance
with the FDA-aligned masking plan, with key secondary endpoints at Weeks 56 and 
                                       96                                       
                                                                                
 SOL-X enrollment continues with plans to implement every 48-week dosing in the 
           open-label protocol based on the durability shown in SOL-1           
                                                                                
       HELIOS-3 Phase 3 Diabetic Retinopathy trial enrollment progressing       
                                                                                
   Commercial readiness activities accelerated with investments in commercial   
   infrastructure, market access planning, and launch execution capabilities    
                                                                                
   Ocular appoints Riad Sherif, MD, to Board of Directors, bringing extensive   
      global commercial experience at Alcon, Novartis, Sanofi, and Oculis       
                                                                                
 Cash balance of $530.6 million as of September 30, 2026, with expected runway  
                                   into 2028                                    
BEDFORD, MA, November 9, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc.
(NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to
redefining the retina experience, today reported financial results for the third
quarter ended September 30, 2026, and provided recent business highlights
including upcoming NDA submission plans for AXPAXLI™ (also known as OTX-TKI),
its investigational product candidate for the treatment of wet age-related
macular degeneration (wet AMD) and diabetic retinal diseases.

“2026 has been a transformational year for Ocular Therapeutix and we are in a
strong position as we prepare to submit our NDA for AXPAXLI in wet AMD under the
505(b)(2) regulatory pathway,” said Pravin U. Dugel, MD, Executive Chairman,
President and CEO of Ocular Therapeutix. “Frequent injections define today’s wet
AMD treatment experience, and we believe AXPAXLI has the transformative
potential to drastically reduce the burden on patients and caregivers. Following
our positive pre-NDA meeting in September, we remain aligned with the FDA on our
planned submission in the fourth quarter. Recent clinical results from our peers
underscore the critical importance of molecular potency, sustained durability,
and thoughtful clinical trial design – principles that have guided our AXPAXLI
development strategy from the outset. SOL-1 post-hoc analyses presented at AAO
reinforce AXPAXLI's remarkable sustained anatomical control, with approximately
70% of subjects who were quantitatively dry at Week 8 remaining dry through Week
36 following a single injection, using a strict AI-based fluid analysis that
detects even trace fluid. At last week’s Empire Forum in New York City, we
presented additional post hoc analyses showing that approximately 28% of
AXPAXLI-treated subjects in SOL-1 experienced early persistent retinal fluid.
These patients had worse visual outcomes, increased variability in total retinal
fluid volume, increased need for supplemental injections, and a 32-week earlier
time to first supplemental injection compared to subjects without early
persistent fluid in the same period. These findings are particularly encouraging
for SOL-R, which was deliberately designed with the goal of randomizing patients
with minimal early retinal fluid and fluid variability. Preliminary analyses of
SOL-R screening indicate that approximately 20% of otherwise eligible subjects
were excluded from randomization due to early persistent retinal fluid or fluid
variability. By contrast, this volatile group of patients were not excluded from
SOL-1. The combination of axitinib’s differentiated potency, AXPAXLI’s disease
control and durability shown in SOL-1, and our disciplined patient selection
strategy further strengthens our confidence in the likelihood of SOL-R’s
success.”

Dr. Dugelconcluded, “With the competitive landscape evolving, AXPAXLI is now the
only intravitreal sustained release maintenance agent with positive Phase 3 data
in wet AMD. We believe our opportunity to fundamentally transform the treatment
paradigm has never been greater. As such, we are rapidly advancing our
commercial readiness, including the addition of Dr. Riad Sherif to our Board of
Directors, who brings extensive global commercial experience in ophthalmology at
Alcon, Novartis, Sanofi, and Oculis. We continue to progress our diabetic
retinopathy program in parallel, as we work expeditiously toward bringing
AXPAXLI to patients who urgently need more durable treatment options as quickly
as possible.”

Peter K. Kaiser, MD, Chief Development Officer of Ocular Therapeutixadded,
“Building on AXPAXLI’s demonstrated durability in SOL-1, we have modified SOL-X
to evaluate retreatment every 48 weeks. This change reflects our confidence in
AXPAXLI’s sustained disease control with up to 12-month dosing. We expect SOL-X
will provide valuable evidence supporting AXPAXLI’s potential role as a long-
term maintenance therapy following a brief course of bolus anti-VEGF injections
to achieve initial retinal dryness. SOL-R further supports dosing flexibility by
evaluating AXPAXLI retreatment every six months. While SOL-R efficacy data are
not required for our planned NDA submission, the trial remains important to our
U.S. commercial and ex-U.S. regulatory objectives. Following our May Type C
meeting we moved the SOL-R primary endpoint to Week 40 to ensure all subjects
complete their primary efficacy assessments beforethe planned Week 52 interim
safety analysis to preserve the primary endpoint’s statistical integrity and
limit operational bias. As we continue to learn more about AXPAXLI, and the
population randomized to SOL-R, our confidence in the trial’s success and
AXPAXLI’s potential to dramatically reduce treatment burden has never been
greater.”

Recent Achievements and Upcoming Milestones:
                                                                                
     Following                                                                  
     completion of positive Pre-NDA Meeting in September 2026, AXPAXLI New      
     Drug Application (NDA)                                                     
     submission on track for 4Q 2026. Consistent with prior communications,     
     the planned AXPAXLI                                                        
     NDA for wet AMD will be supported by SOL-1 Week 52 efficacy data, SOL-1    
     and interim SOL-R                                                          
     Week 52 safety data, and confirmatory evidence. In connection with the     
     NDA review process,                                                        
     Ocular plans to submit data from subjects who have received multiple       
     AXPAXLI injections in                                                      
  ·  both Phase 3 trials to support the inclusion of repeat dosing on           
     AXPAXLI’s label, if                                                        
     approved. Ocular believes its extensive regulatory engagement, including   
     the Special Protocol                                                       
     Assessment (SPA) agreement for SOL-1 and positive Type C and Pre-NDA       
     meetings, provide a                                                        
     strong foundation for its planned NDA submission. In alignment with the    
     FDA, Ocular intends                                                        
     to submit the AXPAXLI NDA under the 505(b)(2) regulatory pathway, which    
     has the potential                                                          
     to shorten the FDA review timeline by up to 60 days as compared to the     
     traditional 505(b)(1)                                                      
     pathway for a new molecular entity.                                        
                                                                                
                                                                                
     Interim                                                                    
     SOL-R Week 52 safety analysis to be conducted in 4Q 2026, with interim     
     safety data to be                                                          
     included in the planned AXPAXLI NDA submission to FDA. Together with the   
     existing SOL-1                                                             
     safety database, the interim safety analysis of SOL-R subjects who have    
     reached Week 52 will                                                       
     bring the aggregate safety dataset to more than 300 patients with at       
  ·  least one year of follow-up                                                
     after AXPAXLI treatment, in line with FDA requirements. The interim SOL-R  
     Week 52 safety                                                             
     results will be included in the NDA submission to the FDA. SOL-R will      
     remain masked through                                                      
     the end of Year 2 (Week 96) as part of the masking plan aligned to with    
     the FDA. This approach                                                     
     is intended to support the Company's regulatory strategy in the United     
     States and internationally.                                                
                                                                                
                                                                                
     SOL-R                                                                      
     primary endpoint timing updated to Week 40 with topline results on track   
     for 1Q 2028 after                                                          
     key secondary endpoints are evaluated. Ocular has updated the timing of    
     the SOL-R primary                                                          
     efficacy endpoint from Week 56 to Week 40, while maintaining key           
     secondary endpoints at Weeks                                               
     56 and 96. The modification was necessary to preserve the integrity of     
     the ongoing masked                                                         
     trial by ensuring all subjects have passed the new primary endpoint visit  
     before the planned                                                         
  ·  interim Week 52 safety analysis takes place. SOL-R will remain masked      
     through Week 96 to                                                         
     evaluate key secondary and other secondary endpoints of superiority to     
     aflibercept (8 mg),                                                        
     along with prevention of fibrosis and atrophy relative to aflibercept (2   
     mg). The process                                                           
     to modify the timing of the primary endpoint was initiated in May 2026     
     after the Company’s                                                        
     Type C Meeting, with subsequent FDA engagement, protocol integration, IRB  
     approval, and FDA                                                          
     alignment completed ahead of the upcoming planned interim safety           
     analysis.                                                                  
                                                                                
                                                                                
     Recent                                                                     
  ·  SOL-1 post hoc analyses further illustrate AXPAXLI’s potential for         
     sustained anatomical                                                       
     control and reinforce SOL-R patient selection strategy.                    
                                                                                
A post hoc analysis presented at the 2026 American Academy of Ophthalmology
(AAO) Annual Meeting reported that at Week 8 in SOL-1, 71% of AXPAXLI-treated
subjects were quantitatively dry (≤10nL total retinal fluid volume in 6x6 OCT
scan) using an AI-based analysis that detects even trace fluid. Of these
subjects, approximately 70% remained quantitatively dry using this very strict
criteria through Week 36, highlighting durability of anatomical control in
patients who achieved early disease stability in SOL-1.

A subsequent SOL-1 post-hoc analysis presented at the 2026 Empire Forum reported
that 28% of the AXPAXLI-treated subjects in SOL-1 had early persistent fluid,
defined as change in central subfield thickness (CSFT) of >30µm from baseline at
Week 8. It is unlikely that these subjects would have qualified for
randomization in SOL-R, based on the non-inferiority trial’s exclusion criteria
during the screening period. Subjects with early persistent fluid in SOL-1 had
worse visual outcomes, a 32-week earlier time to supplemental injection, and an
increased frequency of needing supplemental injections, compared to subjects
without early persistent fluid in the same period.

These post hoc analyses reinforce the Company's confidence in AXPAXLI's
potential to deliver predictable, sustained disease control with significantly
fewer injections than currently available therapies.
                                                                                
     Preliminary                                                                
     analysis of screen failures in SOL-R indicates that approximately 20% of   
     otherwise eligible                                                         
     subjects were excluded due to early persistent fluid or fluid              
     fluctuations. These findings                                               
     provide additional support for the SOL-R study’s differentiated design,    
     which incorporates                                                         
     a six-month pre-randomization period to screen-out patients with high      
     fluid fluctuations                                                         
  ·  and select patients without early persistent fluid for randomization. The  
     approximate 20%                                                            
     of otherwise eligible subjects that were excluded due to early persistent  
     fluid or fluid                                                             
     fluctuations aligns with Ocular’s expectations prior to SOL-R, based on    
     historical                                                                 
     literature, and is validated by similar findings in SOL-1. Together,       
     these findings provide                                                     
     confidence that SOL-R is randomizing the intended patient population and   
     increases the Company’s                                                    
     conviction in SOL-R’s potential success.                                   
                                                                                
                                                                                
     Commercial                                                                 
     readiness advancing rapidly as AXPAXLI is well positioned to potentially   
     be the first intravitreal                                                  
     sustained release maintenance agent approved for wet AMD. Ocular           
     continues to advance                                                       
     commercial readiness activities in anticipation of a potential U.S.        
     launch of AXPAXLI, if                                                      
  ·  approved, with ongoing investments in commercial infrastructure, market    
     access planning,                                                           
     and launch execution capabilities. Ocular’s market research indicates      
     strong physician                                                           
     interest in AXPAXLI’s profile based on SOL-1 data alone and launch         
     planning activities                                                        
     are designed to support rapid physician adoption and broad patient access  
     following a potential                                                      
     regulatory approval.                                                       
                                                                                
                                                                                
     Ocular                                                                     
     Therapeutix appoints Riad Sherif, MD, to Board of Directors, who joins     
     Ocular with extensive                                                      
     global commercial leadership experience spanning Alcon, Novartis, Sanofi,  
     and Oculis. Dr.                                                            
     Sherif will overlap with Seung Suh Hong, PhD, until the end of this year,  
     at which point                                                             
  ·  Dr. Hong will step down from the Board. Dr. Sherif is an accomplished      
     ophthalmology executive                                                    
     with decades of commercial strategy, organizational leadership and global  
     market development                                                         
     experience. As Ocular advances AXPAXLI toward potential regulatory         
     approval, the Company                                                      
     believes Dr. Sherif’s strategic insights and commercial perspective will   
     be tremendous                                                              
     assets to our Board.                                                       
                                                                                
Dr. Sherif currently serves as Chief Executive Officer and Director of Oculis
Holding AG. Prior to joining Oculis, Dr. Sherif served as Entrepreneur in
Residence at the Novartis Venture Fund from 2016 to 2017. Previously, he served
as President of Europe, Middle East and Africa at Alcon from 2014 to 2016, where
he held senior leadership responsibility across a broad international
ophthalmology business. In addition to his leadership role at Oculis, Dr. Sherif
currently serves as a member of the Board of Directors of Revenio Group
corporation.
                                                                                
     SOL-X                                                                      
     (wet AMD) enrollment momentum continues as Ocular plans to modify the      
     dosing cadence to every                                                    
     48 weeks. To date, the vast majority of trial investigators and eligible   
     patients have                                                              
     chosen to participate in SOL-X. Subjects who have successfully completed   
     two-year follow-up                                                         
     in either SOL-1 or SOL-R are eligible to enroll in the three-year          
  ·  open-label extension study                                                 
     evaluating the long-term safety and outcomes of AXPAXLI treatment. Based   
     on AXPAXLI’s                                                               
     demonstrated durability of up to 48 weeks in SOL-1, Ocular plans to        
     modify the SOL-X dosing                                                    
     interval to reflect potential durability of real-world dosing of AXPAXLI.  
     Ocular believes                                                            
     sustained VEGF suppression with AXPAXLI may reduce the incidence of        
     fibrosis and atrophy                                                       
     in wet AMD, thereby improving long-term outcomes.                          
                                                                                
Together, the Company’s three wet AMD trials serve distinct and complementary
objectives. SOL-1 demonstrated AXPAXLI’s superiority to a single aflibercept (2
mg) injection, with durability extending beyond 48 weeks in many subjects. SOL-R
is designed to demonstrate non-inferiority to Q8W aflibercept (2 mg) and that
AXPAXLI can be safely dosed every six months in all subjects, while also
evaluating AXPAXLI’s potential superiority to aflibercept (8 mg). SOL-X will
evaluate durable 48-week dosing intervals and the potential long-term visual and
anatomical benefits of initiating AXPAXLI treatment earlier in the disease
course. Collectively, these studies are designed to support a comprehensive
clinical profile that reinforces AXPAXLI’s potential efficacy, durability, and
flexibility in clinical practice.
                                                                                
     HELIOS-3                                                                   
     (Phase 3, non-proliferative diabetic retinopathy, NPDR) enrollment         
     progressing as Ocular’s                                                    
     potential single registrational trial in diabetic retinopathy. HELIOS-3    
  ·  evaluates AXPAXLI                                                          
     dosed every 12 months (Q48W) versus sham in approximately 620 patients     
     and is designed to                                                         
     support a potential broad label in diabetic retinal disease, including     
     patients with non-center-involved                                          
     diabetic macular edema (DME).                                              
                                                                                
Third Quarter Ended September 30, 2026, Financial Results:

Total cash and cash equivalentswere $530.6 million as of September 30, 2026.
Based on current plans and related estimates of anticipated cash inflows from
DEXTENZA ®, the Company believes that its current cash balance is sufficient to
support its planned operating expenses, debt service obligations and capital
expenditure requirements into 2028. This cash projection factors in the
completion of the SOL-1 trial and the continued execution of the SOL-R, the
SOL-X and the HELIOS-3 trials. The cash projection includes investment in pre-
commercial activities and preparations for the potential FDA approval and
initial launch of AXPAXLI. It does not include the full expenses the Company
anticipates it needs to scale its manufacturing capacity and commercial team, if
approved.

Total net revenuewas $12.9 million for the third quarter of 2026, compared with
$14.5 million for the comparable quarter of 2025.

Research and development expensesfor the third quarter of 2026 were $74.8
million versus $52.4 million for the comparable quarter in 2025. The year over
year increase in R&D expenses resulted from an acceleration in enrollment in the
Company’s HELIOS-3 diabetic retinopathy study and SOL-X long-term extension
study, as well as increased headcount and infrastructure to support expanded
clinical trial activity.

Selling and marketing expenseswere $15.7 million for the third quarter of 2026,
compared with $13.1 million for the comparable quarter of 2025, reflecting an
increase in personnel and pre-commercial investments to prepare for a potential
AXPAXLI wet AMD launch.

General and administrative expenseswere $18.8 million for the third quarter of
2026, compared with $16.0 million for the comparable quarter of 2025 reflecting
increased personnel costs and additional infrastructure to support an increased
scope of clinical trials and manufacturing expansion.

Net loss for the third quarter of 2026was $(94.8) million, or a net loss of
$(0.42) per share on both a basic and diluted basis, compared with a net loss of
$(69.4) million, or a net loss of $(0.38) per share on a basic and diluted
basis, for the comparable quarter of 2025.

Outstanding sharesas of November 06, 2026, were approximately 220.0 million.

Conference Call and Webcast Information:

Ocular Therapeutix will host a conference call and webcast on Monday, November
9, 2026, at 8:00 AM ET to discuss recent business progress and financial results
for the third quarter ended September 30, 2026. To access the call, please dial:
1-833-419-0865 (U.S.) or 1-785-838-9333 (International). The live webcast can be
accessed HERE (Conference ID: OCULAR) and the live and archived webcast can also
be accessed by visiting the Ocular Therapeutix website on the Events and
Presentations section of the Investor Relations page. A replay of the webcast
will be archived for at least 30 days.

About AXPAXLI

AXPAXLI™ (also known as OTX-TKI) is an investigational, bioresorbable,
intravitreal hydrogel incorporating axitinib, a small molecule, multi-target,
tyrosine kinase inhibitor with anti-angiogenic properties, being evaluated for
the treatment of wet AMD and diabetic retinal disease.

The safety and efficacy profile of AXPAXLI has not been established by the FDA
or any other regulatory authority, and AXPAXLI has not been approved for
marketing.

About the SOL-1 Trial

The registrational Phase 3 SOL-1 trial (NCT06223958) is designed to evaluate the
safety and efficacy of AXPAXLI in a multi-center, double-masked, randomized
(1:1), parallel group trial that involves more than 100 clinical trial sites
located in the U.S. and Argentina. In December 2024, the trial completed
randomization of 344 treatment-naïve subjects with a diagnosis of wet AMD in the
study eye. Two randomized subjects withdrew from the trial prior to receiving
Day 1 treatment.

The superiority trial has an eight-week loading segment prior to randomization.
During the loading segment, subjects who have 20/80 vision or better and a
central subfield thickness (CSFT) of ≤500 μm receive two doses of aflibercept (2
mg) at Week -8 and Week -4. Subjects who achieve best corrected visual acuity
(BCVA) of 20/20 at Day 1 (baseline) or gain at least 10 Early Treatment Diabetic
Retinopathy Study (ETDRS) letters at Day 1 along with a CSFT of ≤350 μm were
then randomized to receive a single dose of AXPAXLI (0.45 mg) or a single dose
of aflibercept (2 mg). At Week 52 and at Week 76, all subjects are re-dosed with
their respective initial treatment of AXPAXLI (0.45 mg) or aflibercept (2 mg).
Subjects will be followed for safety until the end of Week 104.

Throughout the trial, subjects are assessed monthly. Trial subjects and
designated trial personnel will remain masked through the end of Week 104. The
clinical trial protocol requires that, during the trial, subjects in either arm
meeting the pre-specified rescue criteria, which include a BCVA loss of ≥15
ETDRS letters from baseline or new vision-threatening macular hemorrhage, will
receive a supplemental dose of aflibercept (2 mg). The protocol provides that
after the first rescue injection, rescue therapy may be provided at investigator
discretion per their clinical judgement.

The primary endpoint of SOL-1 is the proportion of subjects who maintain visual
acuity, defined as a loss of <15 ETDRS letters of BCVA from baseline, at Week
36. Predefined statistical rules were applied to adjust for treatment
discontinuation or deviation as per the pre-specified statistical analysis plan.
The trial remained masked following Week 36 and subjects were evaluated for
treatment durability at Week 52. The trial is being conducted under a Special
Protocol Assessment (SPA) agreement with the FDA.

In February 2026, Ocular reported positive SOL-1 Week 52 topline data. The
superiority primary endpoint was met with 74.1% of subjects in the AXPAXLI (0.45
mg) arm maintaining vision at Week 36, a 17.5% risk difference (p=0.0006),
compared to the aflibercept (2 mg) arm. A key secondary endpoint was met with
65.9% of subjects treated with AXPAXLI (0.45 mg) maintaining vision at Week 52,
a 21.1% risk difference (p<0.0001), compared to the aflibercept (2 mg) arm.

About the SOL-R Trial

The registrational Phase 3 SOL-R trial (NCT06495918) is designed to evaluate the
safety and efficacy of AXPAXLI in a multi-center, double-masked, randomized
(2:2:1), three-arm trial that includes sites located in the U.S., Argentina,
India, and Australia in subjects who are treatment-naïve or were diagnosed with
wet AMD in the study eye within about four months prior to enrollment. Further,
to qualify for screening, a subject’s study eye must have had a BCVA ETDRS
letter score of ≥34 (~20/200). In December 2025, the trial completed the
randomization of 640 subjects.

This non-inferiority trial includes a patient enrichment strategy over the six
months prior to randomization that includes three screening doses of any anti-
VEGF therapy, excluding brolucizumab-dbll, and monitoring to exclude those
subjects with early persistent fluid or significant retinal fluid fluctuations.
Subjects who continue to meet eligibility, defined as a CSFT of ≤350 μm at Week
-12 and Week –8, with ≤35 μm CSFT increase at Week -8 from the lowest CSFT at
any prior visit, entered a run-in period and received two loading doses of
aflibercept (2 mg) prior to Day 1. Subjects in the first arm receive a single
dose of AXPAXLI (0.45 mg) at Day 1 and are re-dosed at Weeks 24, 48, and 72.
Subjects in the second arm receive aflibercept (2 mg) on Day 1 and per label
every eight weeks thereafter. Subjects in the third arm receive a single dose of
aflibercept (8 mg) at Day 1 and are re-dosed at Weeks 24, 48, and 72, aligned
with the AXPAXLI treatment arm for adequate masking. Subjects will be followed
for safety until the end of Week 96. Throughout the trial, subjects are assessed
monthly. Trial subjects and designated trial personnel will remain masked
through the end of Week 96. Subjects in any arm that meet pre-specified rescue
criteria will receive a supplemental dose of aflibercept (2 mg). The pre-
specified rescue criteria include a >5-letter loss in visual acuity plus a ≥75
μm increase in CSFT.

The primary endpoint of SOL-R is to demonstrate non-inferiority in mean BCVA
change from baseline between the AXPAXLI and on-label aflibercept (2 mg) arms at
Week 40. The non-inferiority margin for the lower bound of the 95% confidence
interval is -4.5 letters of mean BCVA when compared to aflibercept (2 mg) dosed
every eight weeks.

About the SOL-X Trial

The SOL-X trial (NCT07516132) is a multi-center, 36-month open-label extension
trial designed to evaluate the long-term safety, efficacy, and disease modifying
potential of AXPAXLI in wet AMD for subjects who have successfully completed
their two-year safety follow-up visits in either the SOL-1 or SOL-R trials. The
first subject enrolled in the study in April 2026.

According to the trial design, all subjects will be given AXPAXLI every 48
weeks, starting at Day 1 (after completion of the Week 104 visit in SOL-1, or
Week 96 visit in SOL-R), and again at Weeks 48, and 96. Subjects are assessed at
Week 4, Week 12, and then every 12 weeks thereafter. Additional visits can be
conducted with supplemental anti-VEGF injection administered based on
investigator discretion.

The primary objectives of SOL-X are to evaluate the long-term safety of AXPAXLI;
to explore long-term visual outcomes, including visual acuity and the incidence
and/or progression of fibrosis and macular atrophy; and to evaluate the impact
of delayed initiation of AXPAXLI in patients who initially were randomized to
receive aflibercept in either SOL-1 or SOL-R.

About the HELIOS-3 Trial

The registrational Phase 3 HELIOS-3 trial (NCT07235085) is designed to evaluate
the safety and efficacy of AXPAXLI in a multi-center, double-masked, randomized
(1:1) two-arm superiority trial. The trial is designed to enroll approximately
620 subjects with moderately severe to severe non-proliferative diabetic
retinopathy (NPDR) without center-involved diabetic macular edema (CI-DME). The
first patient was randomized in the HELIOS-3 trial in November 2025.

Subjects in the first arm receive a single dose of AXPAXLI at Day 1 and are re-
dosed at Week 48. Subjects in the second arm receive a sham injection at Day 1
and Week 48 aligned with the AXPAXLI treatment arm for adequate masking.
Throughout the trial, subjects are assessed every 4 weeks from Day 1 through
Week 56 and every other month thereafter through Week 96.

The primary endpoint of HELIOS-3 is the ordinal diabetic retinopathy severity
score (DRSS) 2-step change status at Week 56 from baseline (≥2-step improvement,
≥2-step worsening, less than 2-step change in either direction).

About Wet AMD

Wet age-related macular degeneration (wet AMD) is a leading cause of severe,
irreversible vision loss affecting approximately 14.8 million individuals
globally and 1.8 million in the United States alone. Wet AMD causes vision loss
due to abnormal new blood vessel growth and hyperpermeability and associated
retinal vascularity in the macula, which is primarily stimulated by local
upregulation of vascular endothelial growth factor (VEGF). Without prompt and
continuous treatment to control this exudative activity, patients develop
irreversible vision loss. With proper treatment, patients may maintain visual
function for a period of time and may temporarily regain lost vision. Challenges
with current therapies include pulsatile, repeated intraocular injections,
treatment-related adverse events and up to 40% patient discontinuation within
one year of initiating treatment with continued disease progression. Taken
together, these factors lead to undertreatment and a lack of long-term vision
improvement for patients.

About Diabetic Retinal Disease

Diabetic retinal disease is an increasingly prevalent global health concern,
driven by the rapidly rising number of individuals diagnosed with diabetes each
year.

Diabetic retinopathy (DR) is the most common category of retinal diseases,
affecting over an estimated 103 million people worldwide. DR is a progressive
condition in which retinal blood vessels are damaged following a cascade of
events triggered by chronically elevated levels of blood glucose. As many as
half of all diabetic patients are expected to develop some form of DR in their
lifetime. DR can progress from the non-proliferative (NPDR) stages to the
proliferative (PDR) stage characterized by the growth of abnormal new blood
vessels. Fewer than 1% of the 6.4 million NPDR patients in the U.S. receive
treatment today, despite the availability of anti-VEGF therapies approved for
the indication, largely due to the burden of frequent injections.

Diabetic macular edema (DME) is also a leading cause of vision loss in the
working-age population. DME, the result of an accumulation of fluid in the
macula that can afflict patients with diabetes, can occur at any stage of DR. In
patients with DME, blood vessels in the eyes leak and start to swell, which can
cause vision loss or blindness. Anti-VEGF drugs are approved to treat DME, but
these treatments typically require frequent intravitreal injections, placing a
significant burden on patients and physicians alike.

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to
redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s
investigational product candidate for retinal disease, is an axitinib
intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-
based formulation technology. AXPAXLI is currently in Phase 3 clinical trials
for wet age-related macular degeneration (wet AMD) and diabetic retinal disease,
including non-proliferative diabetic retinopathy (NPDR).

Ocular’s pipeline also leverages the ELUTYX technology in its commercial product
DEXTENZA ®, an FDA-approved corticosteroid for the treatment of ocular
inflammation and pain following ophthalmic surgery in adults and pediatric
patients and ocular itching associated with allergic conjunctivitis in adults
and pediatric patients aged two years or older, and in its investigational
product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has
completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or
ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC
program.

Follow the Company on its website, LinkedIn, or X.

DEXTENZA ®is a registered trademark of Ocular Therapeutix, Inc. The Ocular
Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of
Ocular Therapeutix, Inc.

Forward-Looking Statements

This press release contains forward-looking statements of the Company regarding
its future expectations, plans, and prospects; statements regarding the
development and regulatory status of the Company’s product candidate AXPAXLI
(also known as OTX-TKI), including the Company’s intention to submit and timing
of a new drug application for AXPAXLI for the treatment of wet AMD based on Week
52 efficacy and safety data from the Company’s SOL-1 Phase 3 clinical trial,
Week 52 data from an interim safety analysis to be conducted in the Company’s
SOL-R clinical trial, and confirmatory evidence, and planned amendments to the
clinical trial protocol of the Company’s SOL-X clinical trial; statements
regarding the timing, design, enrollment, randomization, conduct and retention
of subjects in the Company’s ongoing and planned clinical trials for AXPAXLI,
including the SOL-1, SOL-R and SOL-X clinical trials for the treatment of wet
AMD and the HELIOS-3 trial for non-proliferative diabetic retinopathy;
statements regarding the commercial potential of AXPAXLI, including market
research findings; statements regarding the timing of the availability of data
from the SOL-R trial; statements regarding the potential commercialization of
AXPAXLI, including statements regarding the potential pricing and label of
AXPAXLI and the timing of a potential commercial launch of AXPAXLI, if approved;
statements regarding the Company’s plans to leverage the Section 505(b)(2)
pathway and its potential to accelerate the review timeline of the Company’s
planned NDA submission; statements regarding the Company’s cash runway and the
sufficiency of the Company’s cash resources; statements regarding the potential
utility or adoption, if approved, of any of the Company’s product candidates,
including AXPAXLI; and other statements containing the words “anticipate”,
“believe”, “estimate”, “expect”, “intend”, “designed”, “goal”, “may”, “might”,
“plan”, “position”, “predict”, “project”, “target”, “potential”, “will”,
“would”, “could”, “should”, “continue”, and similar expressions, all of which
constitute forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ materially
from those indicated by such forward-looking statements as a result of various
important factors. Such forward-looking statements involve substantial risks and
uncertainties that could cause the Company’s development programs, future
results, performance, or achievements to differ significantly from those
expressed or implied by the forward-looking statements. Such risks and
uncertainties include, among others, uncertainties regarding the initiation,
design, timing, conduct and outcomes of the Company’s ongoing clinical trials,
including the Company’s SOL-1 trial, SOL-R trial, HELIOS-3 trial, and SOL-X
trial; the timing and costs involved in commercializing any product or product
candidate that receives regulatory approval; the risk that the U.S. Food and
Drug Administration, or FDA, will not agree with the Company’s interpretation of
the written agreements under the Special Protocol Assessments for AXPAXLI,
including for the SOL-1 trial, or of the minutes of the Company’s Type C and
Pre-NDA meetings with the FDA; uncertainty as to whether the FDA will accept a
new drug application for AXPAXLI on the basis of a single pivotal clinical
trial, notwithstanding discussions the Company has had with the FDA regarding
its planned NDA submission; uncertainty as to the minimum clinical data required
to demonstrate the safety of a proposed product candidate such as AXPAXLI, even
if the FDA recognizes that only one pivotal clinical trial may be required to
demonstrate efficacy and accepts the Company’s NDA submission; the risk that
even though the FDA has agreed with the overall design of the SOL-1 trial, the
FDA may not find that the data generated by the trial and submitted by the
Company are sufficient to demonstrate the safety and efficacy of AXPAXLI to the
degree necessary to support marketing approval for wet AMD; the risk that the
FDA might not agree to the Company’s design, protocol, and statistical analysis
plan of any of its clinical trials for which the Company has not obtained a
Special Protocol Assessment, including the SOL-R trial; the risk that the
Company and the FDA may not agree on, or maintain agreement with respect to, the
registrational pathway for any of its product candidates, including AXPAXLI;
uncertainty as to whether the Company will be able to timely satisfy the FDA’s
other requirements for regulatory approval of AXPAXLI, including the FDA’s
Chemistry, Manufacturing and Control’s requirements, even if the Company can
satisfy the FDA’s clinical requirements to demonstrate safety and efficacy;
uncertainty as to whether the Company’s NDA will qualify for, or whether the FDA
will agree to review the NDA, if accepted for filing, under the 505(b)(2)
pathway, notwithstanding discussions the Company has had with the FDA regarding
its planned regulatory pathway, and whether the 505(b)(2) pathway will provide
any time-savings as compared to the traditional 505(b)(1) pathway; uncertainty
as to what restrictions, if any, may be imposed on the label for AXPAXLI, if
approved, pending the receipt of additional clinical data or otherwise;
uncertainty as to whether the data from earlier clinical trials will be
predictive of the data of later clinical trials, particularly later clinical
trials that have a different design or utilize a different formulation than the
earlier trials, whether preliminary or interim data from a clinical trial or
post-hoc analyses of clinical data will be predictive of final data from such
trial, or whether data from a clinical trial assessing a product candidate for
one indication will be predictive of results in other indications; uncertainty
as to the Company’s ability to retain regulatory approval of any product or
product candidate that receives regulatory approval; uncertainty as to whether
data from the Company’s SOL-X trial will demonstrate additional clinically
meaningful, long-term benefits; uncertainties regarding the potential commercial
advantages and/or position of the Company’s product candidates; uncertainty
regarding the implementation and impact of most-favored-nation and other
reference pricing regimes on the commercial potential of AXPAXLI, especially in
markets outside the United States; availability of data from clinical trials and
expectations for regulatory submissions and approvals; the Company’s scientific
approach and general development progress; uncertainties inherent in estimating
the Company’s cash runway, future expenses and other financial results,
including its ability to fund future operations, including clinical trials; the
Company’s existing indebtedness and the ability of the Company’s creditors to
accelerate the maturity of such indebtedness upon the occurrence of certain
events of default; and other factors discussed in the “Risk Factors” section
contained in the Company’s quarterly and annual reports on file with the
Securities and Exchange Commission. In addition, the forward-looking statements
included in this press release represent the Company’s views as of the date of
this press release. The Company anticipates that subsequent events and
developments may cause the Company’s views to change. However, while the Company
may elect to update these forward-looking statements at some point in the
future, the Company specifically disclaims any obligation to do so, whether as a
result of new information, future events or otherwise, except as required by
law. These forward-looking statements should not be relied upon as representing
the Company’s views as of any date subsequent to the date of this press release.

Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
[email protected]
                            Ocular Therapeutix, Inc.                            
                                                                                
                          Consolidated Balance Sheets                           
                                                                                
                (in thousands, except share and per share data)                 
                                                                                
                                  (Unaudited)                                   
                                                                                
  Assets                                                                        
  Current          September 30,                   December 31,                 
  assets:          2026                            2025                         
 ────────────────────────────────────────────────────────────────────────────── 
  Cash and cash    $                 530,612       $                737,060     
  equivalents                                                                   
  Accounts                                                                      
  receivable,                         31,388                         30,650     
  net                                                                           
  Inventory                            4,260                          3,564     
  Prepaid                                                                       
  expenses                                                                      
  and other                            8,340                         10,855     
  current                                                                       
  assets                                                                        
  Total current                      574,600                        782,129     
  assets                                                                        
  Property and                                                                  
  equipment,                          20,281                         19,676     
  net                                                                           
  Restricted                           1,614                          1,614     
  cash                                                                          
  Operating                            5,926                          4,638     
  lease assets                                                                  
  Other                                                                         
  non-current                          3,226                              —     
  assets                                                                        
  Total assets     $                 605,647       $                808,057     
  Liabilities                                                                   
  and                                                                           
  Stockholders’                                                                 
  Equity                                                                        
  Current                                                                       
  liabilities:                                                                  
  Accounts         $                   5,745       $                  4,154     
  payable                                                                       
  Accrued                                                                       
  expenses and                        54,440                         43,835     
  other current                                                                 
  liabilities                                                                   
  Operating                                                                     
  lease                                2,832                          2,817     
  liabilities                                                                   
  Total current                       63,017                         50,806     
  liabilities                                                                   
  Other                                                                         
  liabilities:                                                                  
  Operating                                                                     
  lease                                                                         
  liabilities,                         3,646                          2,815     
  net                                                                           
  of current                                                                    
  portion                                                                       
  Derivative                           9,547                         13,903     
  liability                                                                     
  Deferred                            14,000                         14,000     
  revenue                                                                       
  Notes                               73,535                         71,336     
  payable, net                                                                  
  Other                                                                         
  non-current                            953                            887     
  liabilities                                                                   
  Total                              164,698                        153,747     
  liabilities                                                                   
  Commitments                                                                   
  and                                                                           
  contingencies                                                                 
  Stockholders’                                                                 
  equity:                                                                       
  Preferred                                                                     
  stock,                                                                        
  $0.0001 par                                                                   
  value;                                                                        
  5,000,000                                                                     
  shares                                                                        
  authorized                                                                    
  and no shares                            —                              —     
  issued or                                                                     
  outstanding                                                                   
  at September                                                                  
  30, 2026 and                                                                  
  December 31,                                                                  
  2025,                                                                         
  respectively                                                                  
  Common stock,                                                                 
  $0.0001 par                                                                   
  value;                                                                        
  400,000,000                                                                   
  and                                                                           
  400,000,000                                                                   
  shares                                                                        
  authorized                                                                    
  and                                                                           
  219,884,956                             22                             22     
  and                                                                           
  215,927,600                                                                   
  shares issued                                                                 
  and                                                                           
  outstanding                                                                   
  at September                                                                  
  30, 2026                                                                      
  and December                                                                  
  31, 2025,                                                                     
  respectively                                                                  
  Additional                                                                    
  paid-in                          1,860,107                      1,811,311     
  capital                                                                       
  Accumulated                     (1,419,180  )                  (1,157,023  )  
  deficit                                                                       
  Total                                                                         
  stockholders’                      440,949                        654,310     
  equity                                                                        
  Total                                                                         
  liabilities                                                                   
  and              $                 605,647       $                808,057     
  stockholders’                                                                 
  equity                                                                        
                                                                                
                            Ocular Therapeutix, Inc.                            
                                                                                
          Consolidated Statements of Operations and Comprehensive Loss          
                                                                                
                (in thousands, except share and per share data)                 
                                                                                
                                  (Unaudited)                                   
                                                                                
          Three                                Nine                             
          Mont…                                Mon…                             
          Ended                                End…                             
          Sept…                                Sep…                             
          30,                                  30,                              
  Rev…    2026               2025              2026              2025           
 ────────────────────────────────────────────────────────────────────────────── 
  Pro…                                                                          
  rev…    $      12,8…       $     14,5…       $     37,1…       $     38,…     
  net                                                                           
  Col…               —                 —                 —              128     
  rev…                                                                          
  Tot…                                                                          
  rev…           12,8…             14,5…             37,1…             38,…     
  net                                                                           
  Cos…                                                                          
  and                                                                           
  ope…                                                                          
  exp…                                                                          
  Cost                                                                          
  of             1,455             1,774             4,795             4,9…     
  pro…                                                                          
  rev…                                                                          
  Res…                                                                          
  and            74,7…             52,3…             195,…             146…     
  dev…                                                                          
  Sel…                                                                          
  and            15,6…             13,0…             49,5…             40,…     
  mar…                                                                          
  Gen…                                                                          
  and            18,8…             16,0…             60,9…             46,…     
  adm…                                                                          
  Tot…                                                                          
  cos…                                                                          
  and            110,…             83,2…             310,…             238…     
  ope…                                                                          
  exp…                                                                          
  Loss                                                                          
  from           (97,…  )          (68,…  )          (273…  )          (20…  )  
  ope…                                                                          
  Oth…                                                                          
  inc…                                                                          
  (ex…                                                                          
  Int…           4,978             3,729             16,4…             11,…     
  inc…                                                                          
  Int…           (2,8…  )          (3,0…  )          (8,3…  )          (9,…  )  
  exp…                                                                          
  Cha…                                                                          
  in                                                                            
  fair                                                                          
  val…             912             (1,4…  )          3,056             (3,…  )  
  of                                                                            
  der…                                                                          
  lia…                                                                          
  Gain                                                                          
  on                                                                            
  sale                                                                          
  of                 —                 —                 —               29     
  pro…                                                                          
  and                                                                           
  equ…                                                                          
  Tot…                                                                          
  oth…                                                                          
  inc…           3,076              (720  )          11,1…             (1,…  )  
  (ex…                                                                          
  net                                                                           
  Net     $      (94,…  )    $     (69,…  )    $     (262…  )    $     (20…  )  
  loss                                                                          
  Net                                                                           
  loss                                                                          
  per     $      (0.42  )    $     (0.38  )    $     (1.17  )    $     (1.…  )  
  sha…                                                                          
  bas…                                                                          
  Wei…                                                                          
  ave…                                                                          
  com…           225,…             183,…             224,…             175…     
  sha…                                                                          
  out…                                                                          
  bas…                                                                          
  Net                                                                           
  loss                                                                          
  per     $      (0.42  )    $     (0.38  )    $     (1.17  )    $     (1.…  )  
  sha…                                                                          
  dil…                                                                          
  Wei…                                                                          
  ave…                                                                          
  com…           225,…             183,…             224,…             175…     
  sha…                                                                          
  out…                                                                          
  dil…                                                                          
                                                                                

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/OCUL/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.